OIG To Study AWP Prices For Physician-Administered Drugs
Executive Summary
The HHS Office of the Inspector General will conduct studies of AWP with the aim of allowing state Medicaid programs to reimburse physician-administered drugs at a lower price
You may also be interested in...
Federal Upper Limit List Should Include All Eligible Drug Products, OIG Says
The HHS Office of the Inspector General is recommending that the Federal Upper Limit list include all eligible prescription drugs in order to reduce costs in the Medicaid program
Federal Upper Limit List Should Include All Eligible Drug Products, OIG Says
The HHS Office of the Inspector General is recommending that the Federal Upper Limit list include all eligible prescription drugs in order to reduce costs in the Medicaid program
HHS IG To Study EPO, OxyContin Reimbursement In 2004 Reports
The HHS' Inspector General plans to study the "appropriateness" of epoetin alfa Medicare reimbursements for patients who have not been diagnosed with end stage renal disease